Our CEO Stephan Thorgrimsen presented Immunitrack’s efforts in the fight against COVID-19 at Medicon Valley Alliance's annual meeting earlier this month.
Since March of this year, Immunitrack has been involved in multiple strategies and partnerships to build resources that are now being used by researchers, clinicians and vaccine developers working within vaccine development and immune monitoring of COVID-19 patients.
The recent presentation describes how we have deployed our in vitro NeoScreen® epitope prediction platform to undertake the most comprehensive mapping of HLA-restricted CD4+ and CD8+ T cell epitopes from SARS-CoV-2 to date, many of which have been confirmed independently and reported in peer-reviewed publications.
You can learn more about our approach and findings on a YouTube recording of the presentation.
About Medical Valley Alliance
Medicon Valley Alliance (MVA) is a non-profit membership organisation in the Danish-Swedish life science cluster Medicon Valley, which is a part of Greater Copenhagen. MVA has more than 250 members from universities, hospitals, human life science business, regional governments and service providers in the region. The vision of MVA is to be a well-known and respected member-driven contributor to the realisation and positioning of Medicon Valley as the most competitive and vital life science cluster in northern Europe. The annual meeting brings together prominent regional, national and international speakers to address key topics such as life science innovation, commercialisation of R&D, public private partnerships, talent attraction and other issues of importance for the realisation of our vision for the Medicon Valley cluster.
Click here for further details about this year’s annual MVA meeting ▸